Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to influential within their organizations.

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new products, write Noël Theodosiou and Patrick O. Gee.

This Patient Experience Optimization (PXO) model bridges the critical gap where most clinical trial patients drop out before reaching consent.

Eurofins PSS delivers on-site managed laboratory and manufacturing services, covering everything from R&D to QC, method development, and regulatory support, without headcount or compliance burdens ...

For clinical operations leaders facing tighter budgets and higher expectations, patient experience optimization is essential for building trials that patients can successfully navigate.

The vaccine development landscape is rapidly changing, with a shift away from whole-organism based vaccines to recombinant and vector based vaccines. Nucleic acid based vaccines are also up-and-coming ...